Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10
Year: 2024
Type: article
Abstract: Large type 3 and type 4 gastric cancers (GC) have a significantly poor prognosis, primarily due to their high predisposition for peritoneal dissemination. The application of intraperitoneal chemotherapy has emerged as a viable therapeutic strategy for managing GC patients with peritoneal metastasis. This study is planned to enroll 37 resectable large type 3 or type 4 GC patients. These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study’s primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events.Clinical trial registration number: ChiCTR2400083253 (https://www.chictr.org.cn)
Source: Future Oncology
Authors: Zhi-Jian Jin, Sheng Lu, Min Shi, Hong Yuan, Zhong-Yin Yang, Wen-Tao Liu, Zhen-Tian Ni, Xue-Xin Yao, Zi-Chen Hua, Run-Hua Feng, Ya-Nan Zheng, Zhen-Qiang Wang, Zhen-Jia Yu, Ling-Quan Wang, Birendra Kumar Sah, Ming-Min Chen, Zheng-Lun Zhu, Chang-Yu He, Chen Li, Min Yan, Jun Zhang, Zheng-Gang Zhu, Chao Yan
Institutions: Shanghai Jiao Tong University, Ruijin Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4403217319